De Brauw advised Viking Global Investors and General Atlantic on their investment in the Pharvaris Series C funding round.
Pharvaris is a clinical-stage
biopharmaceutical company focused on developing an oral therapy for Hereditary
Angioedema, which is a rare and potentially life-threatening genetic condition.